ArticleChemistry & biodiversity2026
Validated RP-HPLC and Chromogenic UV Methods for Quantification of Ranolazine in Bulk, Plasma, and Nanoformulation as per ICH Q2(R2) and M10 Guidelines.
Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The study was designed to establish and validate simple, precise, and economical analytical methods for the quantitative determination of Ranolazine in compliance with International Council for Harmonisation Q2(R2) and M10 bioanalytical validation guidelines. The aim was to ensure accurate estimation in both pharmaceutical formulations and biological samples. Quantification was carried out using reverse phase high-performance liquid chromatography (RP-HPLC) and UV-visible spectrophotometry. Chromatographic separation was performed on a Phenomenex C18 (250 mm × 4.6mmID × 5um) column using a mobile phase composed of methanol and water (45:55, pH adjusted to 5.5 with glacial acetic acid). The system operated under isocratic conditions at a flow rate of 1.2 mL/min, with detection at 278 nm and an injection volume of 20 µL. In the spectrophotometric method, ranolazine produced a stable chromogenic complex measurable at the same wavelength. Additionally, a nanoformulation of ranolazine was developed via a microemulsion technique, yielding uniform and stable nanoparticles (∼176 nm). Method validation was performed according to ICH Q2(R2) for analytical parameters such as specificity, linearity, accuracy, precision, robustness, LOD, and LOQ, while bioanalytical validation in plasma followed ICH M10 criteria, including selectivity, recovery, matrix effect, and stability. The methods demonstrated excellent linearity with a correlation coefficient (r
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.